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Abstract
Introduction: Cystic fibrosis (CF) is the most common monogenetic autosomal recessive disease in the human population. This 
systemic disease is characterized by changes in multiple organs, mainly in the lung tissue and digestive tract. More than 59% 
of CF patients become sensitized to fungal spores, mostly Aspergillus fumigatus. 5−15% of CF patients develop allergic bron-
chopulmonary aspergillosis. The aim of the study was to analyse the occurrence of yeast and filamentous fungi of the respiratory 
infections in CF patients and evaluation of drug resistance. 
Material and methods: Between 2006 and 2014, mycological evaluation of 42 patients hospitalized at the National Institute of 
Tuberculosis and Lung Diseases was carried out. 
Results: 217 specimens from pulmonary tract were collected from 42 patients with cystic fibrosis. 205 (68%) strains of yeast 
and 96 (32%) filamentous fungi strains were cultured. The most common mould strain was A. fumigatus — 22,2% (67 species). 
All isolates of filamentous fungi were in vitro 100% susceptible to itraconazole, voriconazole, posaconazole and amphotericin B. 
Conclusions: A. fumigatus and C. albicans were the most common etiological agents of fungal respiratory pathogens associated 
with CF patients. A. fumigatus strains were in vitro 100% susceptible to azole and amphotericin B. Two strains of C. albicans and 
one strain of C.tropicalis were non-susceptible to azole (fluconazole, itraconazole and voriconazole). Scedosporium apiospermum 
was resistant to amphotericin B (MIC > 32 mg/l) and susceptible to voriconazole (MIC 0.094 mg/l).
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Introduction
Cystic fibrosis (CF) is a systemic multiorgan 
and chronic condition, in which functional di-
sorders concern mainly exocrine glands located 
mostly in the respiratory and alimentary systems. 
It is the most common monogenetic autosomal 
and recessive disease in white people. It is caused 
by mutations of the single CFTR gene located on 
the long arm of 7th chromosome that is respon-
sible for the production of the CFTR protein 
(cystic fibrosis transmembrane regulator). The 
CFTR protein is a chloride channel that together 
with sodium channel maintain ion balance of 
epithelial cells of the exocrine glands. In case of 
damage or loss of the CFTR protein, secretion of 
chloride ions in cells is lowered or inhibited, and 
sodium ions are absorbed in increased quantities. 
The disturbed transport of electrolytes between 
the interior of epithelial cells and extracellular 
space causes increased water absorption and 
secretion condensation. In the respiratory sys-
tem, mucociliary clearance is impaired, which 
induces development of infection and chronic 
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inflammation leading to progressive lung damage 
(bronchiectasia, postinflammatory fibrosis, cysts 
and emphysematous bullas). Exacerbations in the 
course of chronic bronchopulmonary disease are 
the most frequent cause of hospitalisations, whe-
reas respiratory failure — the most often cause of 
deaths of CF patients [1−5]. 
The main etiological factors of the respiratory 
system infections in CF patients are the following 
bacterial species: Staphylococcus aureus, Ha-
emophilus influenzae, Pseudomonas aeruginosa, 
Burkholderia cepacia complex, Stenotrophomonas 
maltophila and other Gram-negative bacteria and 
nontuberculous mycobacteria. Adult patients may 
be also infected with other microorganisms such 
as viruses (respiratory syncytial virus [RSV], ade-
noviruses, influenza viruses) or fungi (Aspergillus 
spp., Candida spp.) [1, 3, 6]. 
CF patients belong to the group with increasing 
risk of infection with filamentous fungi. It is pos-
sibly related to impaired mechanism of bronchial 
clearance and prolonged stay in the respiratory 
system of inhaled spores of Aspergillus fumigatus 
[7−9]. Mould spores get through the inhalation 
route and settle the mucous membrane of the upper 
airways and further migrate to the lungs [3]. 
Thick mucus in the airways is the source of 
nutrients and a perfect environment for propaga-
tion and development of fungal cells. It was found 
that during infection, fungal cells secrete many 
proteolytic enzymes (proteases, phosphatases), 
which inhibit their phagocytosis and facilitate 
adhesion and colonization in the airways [2, 3]. 
One of the causes of colonization of fungi in 
the respiratory system is the use of broad-spec-
trum antibiotics in treatment of bacterial infec-
tions. The study by Chotrimall showed that the 
use of tobramycin in treatment of P. aeruginosa 
encourages the colonization of filamentous fungi 
A. fumigatus [3]. 
Among the fungal species isolated from the 
airways of CF patients, the most frequent are 
the following: A. fumigatus, A. flavus, A. niger, 
A. terreus and A. nidulans. It is believed that 
A. fumigatus and A. terreus species colonize the 
upper and lower airways of CF patients, causing 
pneumonia, sinusitis, bronchitis or allergic bron-
chopulmonary aspergillosis (ABPA) [1, 3].
ABPA is caused by hypersensitivity to an-
tigens of the fungus that colonizes the airways. 
Differentiation between fungal infection and 
ABPA in CF patients is difficult due to similarity 
of clinical symptoms typical of the two conditions 
[8]. Additionally, the factors that predispose to the 
development of fungal infection are coexisting 
bacterial infections and a general poor condition 
of the patient [3]. 
Besides filamentous fungi such as Aspergil-
lus spp., hyaline fungi such as Scedosporium 
apiospermum (Pseudollescheria boydii) and black 
yeast Exophiala dermatitidis are also isolated from 
the CF airways [1, 3]. Colonization and infections 
with E. dermatitidis occur considerably more 
frequently in the group of patients with pancreas 
failure [3]. The second species most frequently 
isolated from the CF airways (6.5−10%) is the 
filamentous fungus S. apiospermum [3]. S. apio-
spermum are oportunistic microorganisms who-
se spores are commonly found in the patient’s 
environment (soil, water) [3]. It was shown that 
in patients whose the upper airways are colonized 
by S. apiospermum, infections with Pseudomonas 
aeruginosa are less frequent, whereas infections 
with Staphylococcus spp. are more often, inclu-
ding patients treated with penicillins [3]. 
Other mould species such as Paecilomyces 
spp., Penicillium spp., Alternaria spp. or Clado-
sporium spp. are seldom cultured from clinical 
material and possibly do not impact on increased 
manifestation of clinical symptoms of an under-
lying disease [1, 3]. 
The species of yeast-like fungi, C. albicans, 
less frequently C. glabrata, C. parapsilosis, C. tro-
picalis or C. dubliniensis are also isolated from the 
CF airways. Yeast-like fungi colonize the mucous 
membrans of the alimentary tract causing inflam-
mation conditions of the oral cavity, oesophagus 
and genitourinary system [1, 3]. A long-term co-
lonization with yeast-like fungi may occur after 
therapy with antibiotics and steroids [3].
The objective of the study was the characteri-
stics of fungi isolated from the airways of patients 
with cystic fibrosis, hospitalized and treated at 
the National Institute of Tuberculosis and Lung 
Diseases (Instytut Gruźlicy i Chorób Płuc, IGiChP) 
between 2006−2014.
Material and methods
217 specimens were analysed (186 — sputum, 
31 — bronchial washings) collected from the group of 
42 CF patients treated at IGiChP during 2006−2014, 
in whom fungal infection was suspected. 
The material collected from the patients was 
cultured on solid medium Sabouraud Dextrose 
Agar and incubated at the temperature of 28°C 
for 7−10 days. A direct preparation was made of 
each material, then it was evaluated in respect 
of elements typical of fungi, i.e. hyphae, pseudo-
mycelium and blastospores (Fig. 1). The cultured 
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Figure 2. The percentage of fungal species isolated from patients with cystic fibrosis
Figure 1. Hyphae A. fumigatus — microscopic image of a sample of 
sputum from patients with cystic fibrosis (× 200; collection Depart-
ment of Microbiology, Micology Laboratory, Institute of Tuberculosis 
and Lung Diseases)
colonies of yeast-like fungi were identified to 
particular species using culture on chromogenic 
medium ChromAgar Candida (Graso) and incu-
bated at the temperature of 37°C for 48 hours. 
Yeast-like fungi such as Candida spp.: C. albicans, 
C. tropicalis, C. glabrata, C. krusei were identi-
fied on a chromogenic medium according to the 
manufacturer’s recommendations. 
The other species of yeast-like fungi were 
identified using with biochemical test Api ID 32 C 
(bioMérieux) in accordance with the manufactu-
rer’s recommendations. The Api ID 32 C strips were 
read in the Api Extension device (bioMérieux). 
All cultured filamentous fungi were assigned to 
species basing on morphological characteristics of 
the colonies, hyphae, conidiophores and spores. 
Drug-susceptibility of yeast-like fungi non-al-
bicans to 5 — fluorocytosine (5-FC), amphotericin 
B (AMB), fluconazole (FCA), itraconazole (ITR) 
and voriconazole (VOR) was determined in vitro 
using the ATB Fungus 2 and ATB Fungus 3 strips 
(bioMerieux) in accordance with the manufactu-
rer’ recommendations and read in the Api Exten-
sion device. Minimal inhibitory concentration 
(MIC) for A. fumigatus strains was determined 
using E-test method (bioMerieux) with concentra-
tion gradient of amphotericin B (AMB), itracona-
zole (ITR) and voriconazole (VOR). The activity 
of antifungal drugs was estimated on the RPMI 
1640 medium + MOPS (Biomed and bioMérieux). 
The interpretation of results was made basing on 
the recommendations of the American Clinical 
and Laboratory Standards Institute (CLSI) and 
since 2011 — in accordance with the European 
Committee on Antimicrobial Susceptibility Te-
sting (EUCAST). 
Results
Of 217 specimens collected from the airways 
of 42 patients with cystic fibrosis, 205 (68%) 
strains of yeast-like fungi were isolated, and 96 
(32%) strains of filamentous fungi (Table 1, Fig. 2). 
Among yeast-like fungi, 57% (171) of strains were 
identified as C. albicans, 5% (15) — C. tropicalis 
and 4.3% (13) as C. glabrata (Table 1). Other spe-
cies of Candida spp. constituted 1.7% (6). Among 
filamemtous fungi, A. fumigatus species predomi-
nated — 22.2% (67) (Table 1, Fig. 1). There were 
also single cases of A. niger — 0.4% (1) and A. 
flavus — 0.4% (1). Filamentous fungi Penicillium 
spp. species (21 strains) were identified from 13 
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Figure 4. The pair of yeast and filamentous fungi identified from patients with cystic fibrosis
 Figure 3. The number and percentage of the culture strains of yeast, 
mould and mixed culture from patients with cystic fibrosis
Table 1. Species of yeast and mould isolated from pulmo-
nary tract from patients with cystic fibrosis
Species Number of isolates (n = 301)
Yeast 205 (68.0)
C. albicans 171 (57.0)
C. tropicalis 15 (5.0)
C. glabrata 13 (4.3)
C. parapsilosis 2 (0.7)
C. holmii 2 (0.7)
C. krusei 1 (0.3)
C. sake 1 (0.3)
Mould 96 (32.0)
Aspergillus fumigatus 67 (22.2)
Aspergillus flavus 1 (0.3)
Aspergillus niger 1 (0.3)
Aspergillus spp. 4 (1.3)
Scedosporium apiospermum 1 (0.3)
Penicillium spp. 21 (7.0)
Paecilomyces spp. 1 (0.3)
patients. Scedosporium apiospermum was isolated 
from sputum of one patient (0.3%) (Table 1, Fig. 2). 
Of 217 specimens, in 45% (137), yeast-like 
fungi strains were isolated, in 5.3% (16) strains of 
filamentous fungi were recovered, and in 49.2% 
— combined cultures (2 or 3 species) of yeast-like 
and filamentous fungi were found (Fig. 3). In 39 
cases, 2 species of fungi were grown simultaneo-
usly: C. albicans and A. fumigatus. The pairs of 
the following fungi were also cultured: C. albicans 
and Penicillium spp. (9), Aspergillus spp. and 
C. albicans (4), C. albicans and C. tropicalis (3), 
C. albicans and C. glabrata (3) and A. fumigatus 
and C. tropicalis (3) (Fig. 4). 
In vitro susceptibility to antifungal drugs 
was tested for 16 strains of filamentous fungi 
and 12 strains of yeast-like fungi. All 16 strains 
of A. fumigatus showed 100% of susceptibility to 
antifungal drugs from the azole group, i.e. itra-
conazole (MIC 0.25–1.0 mg/l), voriconazole (MIC 
0.064–0.19 mg/l) and to a polyene drug — ampho-
tericin B (MIC 0.19–0.38 mg/ml) (Table 3). Hyaline 
fungus Scedosporium apiospermum, which was 
isolated from sputum, was in vitro susceptible 
to voriconazole (MIC 0.094 mg/l) but it showed 
resistance to amphotericin B (MIC > 32 mg/l) 
and itraconazole (MIC > 32 mg/l) (Table 4). All 
strains of yeast-like fungi of Candida spp. species 
were susceptible to amphotericin B (100%). In the 
case of C. albicans (2 strains), resistance to azoles 
was observed: fluconazole (MIC 4.0 mg/l), itra-
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Table 2. Susceptibility to antifungal agents yeast species isolated from patients with cystic fibrosis (interpretation according 
to EUCAST)
Species 5FC AMB  FCA  ITR  VOR MYK
S I R S I R S I R S I R S I R S I R
C. albicans (n = 1) 1 – – 1 – – 1 – – 1 – – 1 – – – – –
C. albicans (n = 2) – – 1 2 – – – – 2 
(MIC  
4.0 mg/l)
– – 2 
(MIC  
0.19 
mg/l)
– – 2 
MIC  
0.25 
mg/l)
1 – –
C. glabrata (n = 5) 3 – – 5 – – – 4 1 1 3 1 3 – – – – –
C. tropicalis (n = 2) – – – 2 – – 1 – 1 1 – 1 1 – 1 – – –
C. parapsilosis (n = 1) 1 – – 1 – – 1 – – 1 – – 1 – – – – –
C. krusei (n = 1) – – – 1 – – – – 1 – 1 – – – – – – –
5FC — 5-fluorocitosine; AMB — amphotericin B; FCA — fluconazole; ITR — itraconazole; VOR — voriconazole; MYK — micafungin; MIC — minimal inhibitory con-
centration; S — sensitive; I — intermediate; R — resistance
Table 3. MIC50 and MIC90 for antifungal drugs against A. fumigatus strains (interpretation according to EUCAST)
Drug Strains
A.fumigatus 
(n = 16)
MIC50
(mg/l)
MIC90 
(mg/l)
MICRange
 (mg/l)
ITR 16 0.38 1 0.25−1.0
VOR 16 0.125 0.19 0.064–0.19
AMB 6 0.25 0.38 0.19–0.38
POS 1 0.047 0.047 0.047
ITR — itraconazole; AMB — amphotericin B; VOR — voriconazole; POS — posaconazole; MIC — minimal inhibitory concentration
Table 4. Minimal inhibitory concentrations for antifungal 
drugs against Scedosporium apiospermum (in-
terpretation according to EUCAST)
Scedosporium 
apiospermum
VOR ITR AMB
MIC 0.094 mg/l > 32 mg/l > 32 mg/l
VOR — voriconazole; ITR — itraconazole; AMB — amphotericin B; MIC — 
minimal inhibitory concentration
conazole (MIC 0.19 mg/l) and voriconazole (MIC 
0.25 mg/l). These strains were 100% susceptible 
to echinocandin — micafungin (MIC 0.008 mg/l) 
(Table 2). One strain of C. tropicalis and all iso-
lates of C. glabrata (5 strains) showed resistance 
to drugs from the azole group, i.e. fluconazole, 
itraconazole and voriconazole (Table 2).
Discussion
Quality and length of life of CF patients 
depends on the course of bronchopulmonary 
disease and morphological changes in the lung 
parenchyma. The identification of etiological 
factors of infection relies strongly on microbiolo-
gical diagnostics. It enables proper recognition of 
microorganisms of the upper and lower airways, 
and implementation of appropriate treatment. 
Among fungal species responsible for fungal 
infections, a prominent role assign to filamentous 
fungi such as Aspergillus fumigatus, Scedosporium 
apiospermum and Exophiala dermatitidis [10, 11]. 
Filamentous fungi are opportunistic microorga-
nisms living in natural environment. The spores 
of A. fumigatus species nest the respiratory system 
of the patient and producing mycelium, which 
secretes protein allergens. Buarque de Almeida 
et al. showed the role of Asp f1, Asp f2, Asp f4 
and Asp f6 proteins for the development of aller-
gic aspergillosis in CF patients [12]. During the 
development of the disease high concentration of 
allergens in the lungs stimulates immunological 
response of the host. The organism of the patient 
produces specific antibodies, mainly immuno-
globulin E (IgE) and G (IgG), whereas Th2 cells 
influence secretion of proinflammatory cytokines: 
interleukins 4, 5, 13, thus strengthening inflam-
matory process in the tissues [3, 13]. 
The present paper analysed the outcomes of 
microbiological tests of 42 CF patients (>18 years) 
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treated at IGiChP during 2006−2014. Armstead 
et al. in their study revealed data concerning the 
prevalence of cystic fibrosis in patients (>18 
years) in some European countries, the USA, Au-
stralia and Canada [14]. The proportion of adult 
patients with CF oscillated between approxi-
mately 50% in the USA (13,657), France (2,873) 
and Australia (1,556), and about 60% in Canada 
(2,238) [14, 15]. In Poland, the only available data 
on the prevalence of CF > 18 years come from 
the Polish Cystic Fibrosis Working Group (Polska 
Grupa Robocza Mukowiscydozy), which reports 
535 registered patients up to the end of 2012 [16].
The present study evaluated the prevalence 
and drug resistance of fungal pathogens in the 
group of CF patients treated at IGiChP in War-
saw, in whom fungal infection was clinically 
suspected. Mycological diagnostics of CF pa-
tients included culture of the following material: 
sputum, bronchial secretion, bronchoalveolar 
lavage. 205 strains (68%) of yeast-like fungi 
and 96 strains (32%) of filamentous fungi were 
identified. Among yeast-like fungi C. albicans 
(57%) dominated, then C. tropicalis (5%) and C. 
glabrata (4.3%). 1.7% constituted other species of 
Candida. Among filamentous fungi A. fumigatus 
dominated — 22.2%. Comparable proportions 
of yeast-like fungi were obtained by Schabere-
iter-Gurtner et al. In material collected from CF 
patients, Candida species constituted — 64.5%, 
then filamentous fungi — 35.5%, mainly Aspergil-
lus species [15]. Caballero et al. also reported the 
prevalence of yeast-like fungi in the material col-
lected from 35% of CF patients, and filamentous 
fungi isolated from 4% of patients [17]. 
Among the clinical material collected from 
the patients treated at the National Institute of 
Tuberculosis and Lung Diseases dominated spe-
cimens, from which one fungus species (yeast or 
filamentous fungus) was isolated (50%); whereas 
from the remaining material, two (33.3%) or three 
(16.7%) species of yeast-like and/or filamentous 
fungi were recovered (Fig. 5).
In the material from which two or three 
fungal species were recovered simultaneously, 
the most common were two species of fungi: C. 
albicans and A. fumigatus (13%). Corresponding 
results were obtained by Delhaes et al. Two fungal 
specimens C. albicans and A. fumigatus domi-
nated in the material recovered from cultures of 
specimens from CF patients [18]. 
One of the most crucial pathogens responsible 
for fungal infections in CF patients are Aspergillus 
species. Colonization with this pathogen occurs 
usually after infection with Pseudomonas spp. 
Figure 5. The number and percentage fungal species isolated from 
pulmonary tract from patients with cystic fibrosis
and treatment with tobramycin [3, 19]. Liu et al. 
tried to define indicators that distinguish coloni-
zation from infection of Aspergillus spp. etiology 
in the group of people with CF [11]. According 
to the authors, infection with Aspergillus spp. 
is marked by isolation of this species in > 50% 
of sputum specimens collected from the patient 
during the previous 6-12 months, worsened spiro-
metric indices and failure of antibacterial therapy 
[11]. The literature reports rare cases of invasive 
aspergillosis in people with CF. Mortensen et al. 
presented two cases of invasive fungal infection 
of A. fumigatus etiology [20]. However, in the 
majority of CF patients, isolation of Aspergillus 
spp. only confirms colonization and/or diagno-
sis of allergic bronchopulmonary aspergillosis 
(6−25%) [20]. The Danish research showed 65.5% 
of colonization cases of the lower airways with 
Aspergillus spp. and 2.7% of cases of ABPA [20]. 
In Poland, due to lack of register of CF patients 
suspected ABPA, the only available data are 63 
cases of suspected ABPA in CF patients > 18 years 
of age, which were reported in 2007 [14]. 
In the study, drug resistance of A. fumigatus 
strains to drugs from the azole group was tested. 
100% in vitro susceptibility to itraconazole, vori-
conazole, posaconazole and amphotericin B was 
found. However, it should be underlined that 
the literature has already reported the cases of 
resistance of A. fumigatus isolated from people 
with CF to itraconazole (MIC > 1 mg/l), voricona-
zole (MIC > 4 mg/l) and posaconazole (MIC > 4 
mg/l), and resistance to more than one drug from 
the azole group (multi-azole resistance) [21−23].
Resistance to azoles is related to the occur-
rence of mutation in the cyp51A gene, which is 
responsible for ergosterol reaction in the fungal 
cell [20]. Mortensen et al. showed that 4% of 
A. fumigatus strains that were isolated from the 
CF patients, have a lowered susceptibility to azole 
drugs [20]. Fischer et al. found resistance to itra-
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conazole (MIC > 8mg/l) and cross resistance to 
the remaining drugs from the azole group such 
as voriconazole and posaconazole in 3.4% of A. 
fumigatus strains [24]. Burgel et al., similarly, 
showed a lowered susceptibility of A. fumigatus 
strains isolated from the patients > 18 years of 
age to itraconazole [23]. The lowest sensitivity 
of A. fumigatus to azoles was observed among 
the strains recovered from the patients who ear-
lier underwent therapy with azole preparations 
[23−26]. The research carried out among CF 
patients in Germany and Denmark reported an 
alarming resistance of A. fumigatus strains to 
azoles (pan-azole resistance), being probably the 
result of the presence of typical TR46/Y121F/
T289A mutations [24, 27]. The study at IGiChP 
showed low values of MIC of A. fumigatus strains 
for azole drugs: MIC 0.25−1.0 mg/l for itracona-
zole and MIC 0.064−0.19 mg/l for voriconazole. 
Comparable MIC values for azoles were obtained 
by Amorim et al. and Drago et al. [28–30]. The 
results of the researches presented, including the 
own study, suggest that resistance to azoles of A. 
fumigatus strains isolated from CF patients should 
be tested routinely. 
In the present study, special attention has 
been drawn to the isolation of Penicillium spp. 
(7%), which, in the opinion of some researchers, 
is considered to be a new pathogen of respiratory 
infections in people with CF [18]. In the research 
by Valenza et al., filamentous fungi of Penicillium 
spp. species were isolated from 18.3% of CF 
patients [30]. Authors suggest that filamentous 
fungi such as Penicillium spp. may inhibit the 
airways of people with CF for a long time, with 
no signs of clinical infection [11]. Diagnosis is 
difficult because it needs differentiating between 
environmental strains of Penicillium spp. and 
similar of phenotype species: Penicillium emerso-
nii, Rasamsonia spp. and Acrophialophora spp., 
which are described as potential pathogens that 
may cause progressive allergic bronchopulmona-
ry hypersensitivity and invasive fungal infections 
in people with immunity deficiency [3, 31−33]. 
In the present study, hyaline fungus Sce-
dosporium apiospermum was recovered from 
sputum culture of one CF patient. The literature 
reports single cases of isolation of this species in 
people with CF [23, 34]. Edelman et al. discovered 
significant proportions (28.6%) of Scedosporium 
spp. in the patients after lung transplantation. An 
increased number of Scedosporium spp. isolated 
in this group of patients is related probably to the 
therapy with inhaled antibiotics and steroids [35]. 
It was observed that Scedosporium spp. strains 
are usually isolated from CF patients together 
with Aspergillus spp., if Pseudomonas bacteria 
are not present [9]. It should be underlined 
that Scedosporium spp. was isolated from CF 
patients barely in few studies, which may be 
caused by the fact that culture and identifica-
tion of the species is quite difficult. These fungi 
grow better on media Sabouraud Dextrose Agar 
with cycloheximide or dichloran rose bengal 
chloramphenicol [35]. Moreover, compared to 
other filamentous fungi, they require a  longer 
incubation time (about 14 days) at the tempera-
ture from 28°C to 30°C. Furthermore, this species 
is susceptible to a small number of antifungal 
drugs, including voriconazole and posaconazo-
le. In case of infection with Scedosporium spp., 
in particular in immunosuppressed patients, 
mortality reaches 54% [36−38]. The present 
study confirmed susceptibility of Scedosporium 
apiospermum strains to voriconazole (MIC 0.094 
mg/l). The strain proved resistant to amphoteri-
cin B and itraconazole. The research by Biland 
et al. found single cases of resistance of Scedo-
sporium spp. to posaconazole among the strains 
isolated from CF patients who earlier had been 
treated with azoles [37]. 
Drug resistance of yeast-like fungi to anti-
fungal preparations was also analysed. Candi-
da spp. strains showed 100% susceptibility to 
azoles, amphotericin B and micafungin. It was 
observed that two strains of C. albicans isolated 
from one patient with CF, according to the inter-
pretation of the EUCAST guidelines, showed in 
vitro resistance to fluconazole (MIC 4.0 mg/l), 
itraconazole (MIC 0.19 mg/l) and voriconazole 
(MIC 0.25 mg/l). As it was reported in the clinical 
history, the patient underwent therapy with azo-
les in the past. In the study by Chotirmall et al., 
it was demonstrated that resistance of Candida 
species to antifungal drugs may be influenced 
by the ability of these strains to grow in biofilm 
structure [3]. 
The results of the present study and other 
researches prove that fungi, particularly A. fumi-
gatus species are a potential pathogen of severe 
invasive respiratory infections in CF patients 
[39]. Therefore, an efficient antifungal therapy in 
CF patients has to be preceded with mycological 
examination in order to determine etiology of 
infection and drug-sensitivity of the pathogen to 
antibiotics. Currently, there is a need for devel-
oping an algorithm of mycological diagnostics 
of filamentous fungi, in particular the pathogens 
responsible for colonization and infections of CF 
patients [40]. 
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Conclusions
1. In airway samples from 42 CF patients, 
A. fumigatus and C. albicans species dominated. 
2. The evaluation of in vitro drug resistance of 
filamentous fungi showed that A. fumigatus 
were 100% susceptible to the azole drugs and 
amphotericin B.
3. C. albicans strains present resistance to the 
azole drugs: fluconazole, itraconazole and 
voriconazole. 
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